Related Experiment Videos
Xenotransplantation: perspectives from The Netherlands
1Health Council of The Netherlands, Den Haag, The Netherlands. e.van.rongen@gr.nl
Annals of the New York Academy of Sciences
|February 3, 1999
Summary
Xenotransplantation is ethically acceptable but not yet clinically viable due to rejection and safety concerns. Genetically engineered pigs are preferred over primates, but legal frameworks require updates for safe clinical application.
Area of Science:
- Biomedical Ethics
- Transplantation Medicine
- Regulatory Science
Background:
- Xenotransplantation, using animal organs for human recipients, faces ethical approval but practical hurdles.
- Concerns include immune rejection and the potential transmission of zoonotic diseases.
- Current regulations struggle to address the unique challenges of genetically engineered source animals.
Purpose of the Study:
- To assess the ethical acceptability and clinical readiness of xenotransplantation.
- To identify key barriers to clinical application, focusing on safety and regulatory aspects.
- To propose necessary legal and regulatory adjustments for the responsible advancement of xenotransplantation.
Main Methods:
- Review of the Health Council of the Netherlands' report on xenotransplantation.
- Analysis of ethical considerations from human and animal perspectives.
- Evaluation of current legal and regulatory frameworks in the Netherlands and Europe.
Main Results:
- Xenotransplantation is deemed ethically acceptable.
- Clinical application is not yet recommended due to rejection issues and pathogen transmission risks.
- Genetically engineered pigs are the preferred source animals, while non-human primates are unsuitable.
- Existing Dutch and European regulations are inadequate for genetically engineered animals and xenotransplants.
Conclusions:
- Further research is essential to overcome technical and safety challenges.
- Legal and regulatory frameworks require significant revision, including a national law for biologicals.
- International agreements are needed to manage xenotransplantation, potentially by classifying xenotransplants as medicines for regulatory oversight.